A new model-based cost-effectiveness analysis, published in Vaccine, reveals that influenza vaccination in patients with heart failure (HF) is not only clinically beneficial but also economically advantageous compared to usual practice. The study demonstrates that vaccinating HF patients reduces hospitalizations and cardiovascular complications, leading to significant healthcare cost savings. Given the heightened risk of severe flu-related outcomes in this population, the findings support routine influenza immunization as a cost-effective intervention to improve patient outcomes and ease the burden on health systems.
The research highlights the need for broader implementation of vaccination programs targeting high-risk groups, such as those with chronic heart conditions. By incorporating real-world data, the analysis estimates that influenza vaccination in HF patients could prevent numerous adverse events per season, justifying its inclusion in standard care protocols. Policymakers and healthcare providers are encouraged to prioritize vaccine access for this vulnerable group to maximize both health and economic benefits.
Thumbnail image credit: Gavi
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.